The oral treatment of DEN/PB-supplemented rats with MFP inhibited hepatic IL-1β, TNF-α, and NF-κB, thus MFP could improve liver inflammation and thus prevent the progression of HCC. The gene discussed is IL1B; the disease is hepatocellular carcinoma.